Marcellus Investment Managers - One of the Best Portfolio Management Service Companies in India
  • Region
    India USA
  • Our Philosophy
  • Offerings

    Portfolio Management Services (PMS)


    Indian Equities
    Consistent Compounders Rising Giants Little Champs Kings of Capital MeritorQ PMS Curation Portfolio
    Global Equities
    Global Compounders PMS
    Global Equities Fund (Retail)
    Multi Asset
    Multi Asset PMS

    Asset Allocation Services


    Asset Allocation        

    Portfolio Advisory Services


    Indian Equities
    MeritorQ Advisory (Smallcase)        
    Multi Asset
    Aggressive Allocation Balanced Allocation Conservative Allocation
  • Insights

    Newsletters


    Consistent Compounders Kings Of Capital Little Champs Rising Giants Marcellus Erudite MeritorQ PMS Global Compounders

    Insights


    Recents Blogs Newsletters Portfolio Updates 3 Longs and 3 Shorts

    Videos


    Featured Webinars Client Exclusive

    Podcasts


    All MeritorQ Podcasts (English) MeritorQ Podcasts (Hindi)
    Client Exclusive Content

    Others


    Client Exclusive Content Three Longs & Three Shorts Blogs Videos Media Centre
  • Resources
    Support Resources Online Access Guide Marcellus’ Forms UPI Payment
    Disclosure document GIFT City Disclosure PMS Fees Calculator
  • Team
  • PLAN YOUR GOALS
    • Invest Now
      • Portfolio Management Services (PMS)
      • Investment Advisory Services
      • Global Equities Fund (Retail)
  • Subscribe
  • Connect
  • Login
  1. Newsletter
  2. April 2021
Apr 2021 Little Champs

Spotlighting Amrutanjan Healthcare

Published on Apr 09, 2021 · 3 Min Read
This month we place the spotlight on Amrutanjan Healthcare, the second largest player in the Indian head pain balm category. Over the last decade, Amrutanjan has successfully mitigated the growth challenges in its mature core head pain balm category through new products, targeting the adjacencies (body pain, congestion) and foray into categories like sanitary napkins (Comfy). This success has been underpinned by product innovations (like roll-on), a revamped distribution model (moving away from wholesale dependent to direct model), improved processes (investment in technology/automation), an effective go-to-market strategy (right target markets, increased advertising) and most importantly through judicious capital allocation (outsourced manufacturing for Comfy, control on working capital). Inability to attract the required talent and any state intervention in the sanitary napkins segment are key potential risks.

Performance update of the Little Champs Portfolio

At Marcellus, the key objective of our Little Champs Portfolio is to own a portfolio of about 15-20 sector leading franchises with a stellar track record of capital allocation, clean accounts & corporate governance and at the same time high growth potential. While we intend to fill our portfolio with winners, we want to be sure of staying away from dubious names where we are not convinced about the cleanliness of accounts or the integrity of the promoters (even though business potential may sound promising) as the fruits of company’s performance may not get shared with minority shareholders. We intend to keep the portfolio churn low (not more than 25-30% per annum) to reap the benefits of compounding as well as minimize trading costs.

The Little Champs Portfolio went live on August 29, 2019. The performance so far is shown in the below table.

Stock in the Spotlight: Amrutanjan

As stated earlier, we will be communicating our detailed investment rationale on each of our portfolio stocks on a periodic basis. This month we detail our investment rationale for Amrutanjan Healthcare. In the previous months we have written on: Garware Technical Fibre (August 2020), GMM Pfaudler (September 2020), V-Mart Retail (October 2020), Alkyl Amines (November 2020), Suprajit Engineering (December 2020) and Mold-Tek Packaging (February 2021)

Company Background: Amrutanjan Healthcare was founded in 1893 by Kasinadhuni Nageswara Rao. The flagship yellow coloured Amrutanjan headache balm was amongst the first products launched by the Company. Over the years, the group ventured into several businesses like chemicals, non-bank financing, infotech, biotech, etc. However, not only did these other ventures not succeed, they eclipsed the relative success of the core head pain balm venture. In 2005, Sambhu Prasad Sivalenka, a fourth-generation promoter family member, took over as the Managing Director. Upon taking charge, Sambhu divested or closed down most of the non-profitable ventures. Once this objective was achieved, the Company refocused on growth by: (a) Improving the core head pain balm business by revamping the distribution network including geographic expansion beyond southern states, addressing changing market dynamics (towards white coloured balms), product innovations (roll-on), etc; (b) targeting adjacencies like body pain balm segment; and (c) forays into new FMCG categories like beverages and sanitary napkins through a measured capital allocation strategy.

Despite growth challenges in the mature head pain balm category, entry into newer segments like sanitary napkins have enabled Amrutanjan to clock a healthy 12% revenue CAGR over FY10-20, higher than the 5% CAGR clocked over FY2000-10.  Most of Amrutanjan’s products command high gross margin of ~50-60% (gross profit CAGR of 10% over FY10-20). However, in recent years, the Company has invested significantly in advertising & sales promotion spends due to a higher focus on brand building, expansion of distribution in West & North India and entry into new categories such as sanitary napkins (advertising and sales promotion spends as % of revenues increased from 8.5% in FY2014 to 16.6% in FY20). Hence the growth in net profits have lagged that of revenue and gross profit growth. Despite this, Company’s return on invested capital (RoIC) has expanded from 39% in FY10 to 61% in FY20 (despite a hit from Covid in FY20) thanks to improvement in fixed assets turnover (through closing down of loss-making businesses and outsourced manufacturing for Comfy sanitary napkins) and reduction in working capital (from average 40 days in FY10 to 25 days in FY20). Given the accumulation of cash in recent years (net cash of Rs1,050mn at FY20-end), RoCE is lower than RoIC.

What do we like about Amrutanjan?

A. Product innovations and foray into adjacencies to address growth challenges: The head balm market in India is relatively saturated with somewhat less salience amongst the younger generations. Further, over the years the category has been witnessing increased competition from allopathic alternatives like paracetamol. Amrutanjan has addressed this issue in two ways. Firstly, by increasing its addressable market by increasing focus on the Body pain management and Congestion management in recent years. Body pain and Congestion are natural extensions of the Head balm market given the key ingredients as well as the supply chain remain largely similar. Secondly, the company has launched innovative formats for all the pain management products such as roll-ons, sprays and pain-patch which find higher traction with the younger generation. Roll-on has been one of the highly successful innovations for the company in Head & Body pain segments and now forms ~10% of the total net sales.

B. Improving business processes and thus operating efficiency consistently:

  • A revamped distribution model: Until 2009, Amrutanjan mainly followed a wholesale-oriented and pharma distribution model which offers low visibility and control over the channels as well as the lack of direct relationship between the company and the retailer. In 2009, the Company kicked-off an initiative to move from the pharma model to FMCG model of distribution with an intention to increase its direct reach with the chemists and kirana/grocery stores. The share of wholesale sales has come down from ~50%+ of total sales to ~30% of total sales over the last 10 years and the company has now established its direct reach at ~2.5 lakh outlets. At the same time company has been ramping up its presence in Modern Trade which accounted for ~10% of OTC sales in FY20.

 

  • Sales force automation: In 2018, the company initiated work on implementing SalesForce Automation which will further help the firm: (a) obtain granular data on outlets covered/SKUs sold, (b) shift from paper-based order taking to tablet based order taking feeding data directly into ERP, (c) with availability of granular and real time data for analytics and forecasting, and (d) monitor its field force on a real time basis. The biggest benefit of initiatives such as SalesForce Automation for a small company like Amrutanjan has been to overcome the scalability challenges as it expands into West & North India and scale up new categories such as sanitary napkins.

 

  • Increasing use of technology: Amrutanjan has rolled out a company-wide ERP and over the recent years has made further efforts in this direction by digitizing all the internal processes and implementing SalesForce Automation as discussed above. As we had discussed in our 2nd October 2020 newsletter (click here), early adoption of technology helps smaller companies not only overcome scalability related challenges but also generates higher operating efficiencies.

 

  • Improvement in HR processes: Amrutanjan has been improving its HR standards and processes over the recent years to attract and retain professional talent as the company grows and expands. More recently, the company engaged with consultants to design & devise a performance management system to bring it on par with industry standards. Another recent milestone for the company was the launch in 2020 of an Employee Stock Option Plan for the first time in its history.

 

C. Foray into sanitary napkins – potential to be a long- term game changer for the Company: Sanitary napkins is a ~Rs4,000crs market currently in India and has been dominated by Whisper (P&G) and Stayfree (J&J) for many decades. However, it remains a highly under-penetrated category with penetration levels anywhere between ~20-25% only at present due to issues such as lack of availability, awareness, and affordability.

Amrutanjan entered this category in 2013 with its Comfy brand and with a focus on first time users and cloth users in rural/under-developed areas where the penetration levels are even lower due to unavailability of high quality napkins at affordable prices. Amrutanjan has partnered with Bella Hygiene (a leading producer of women hygiene products and machineries in Poland and Eastern Europe) giving it access to superior technology to make a better-quality product and offer it at price which is 20-25% lower than that of the incumbents. This strategy has resulted in reasonable success with Comfy garnering double digit market shares in the Eastern states of Odisha (~17%) and West Bengal helped by relative under-penetration of the category in these states, Amrutanjan’s superior brand equity, distribution and higher advertising spend relative to companies of its size in these markets. Comfy has also helped the company make an entry into North India region (where it has had a weak presence traditionally) by garnering significant market share in parts of Eastern Uttar Pradesh and Madhya Pradesh. Over FY17-20, Comfy sales have grown by ~70% CAGR and currently forms ~15% of the total sales of Amrutanjan. However, despite this high growth, Amrutanjan still has a miniscule share (<2%) in this fast-growing category thus indicating huge opportunities for the Company in this space.

Key risks:

  • Inability to maintain or increase resonance of balms: The preference for balms amongst the younger generation is relatively lower. Additionally, pharma companies are coming with allopathic alternatives supported by aggressive market campaigns. In such a scenario, there is risk of contraction or stagnation in the core balm business. However, so far Amrutanjan’s efforts of launching innovative formats such as roll-ons – which resonate with the younger generation – have worked well.

 

  • Risk to pricing power in sanitary napkins due to competition and government regulations: So far, the sanitary napkin market in India has been dominated by the top 3 players viz Whisper (P&G), Stayfree (J&J) and Sofy (Unicharm). However, over the last few years, to tap the huge potential in this space, several new companies have entered the market and have achieved reasonable scale. Easing of barriers to entry around manufacturing (thanks to cheap Chinese machines), distribution (thanks to the growth of Modern Trade), brand, etc can attract more players further intensifying the competition. Given the huge under-penetration of sanitary napkins in India, there is also a potential risk of Government intervention through subsidized products or price controls to further improve the affordability and availability of sanitary napkins.

 

  • Inability to hire & retain professionals: Fourth generation promoter Sambhu Prasad Sivalenka is the key man at Amrutanjan responsible for major strategic and capital allocation decisions. As the business grows and expands outside its core areas, there is a need to strengthen the management team to avoid growth obstacles. Recent steps such as revamping of performance management systems, formulation of ESOP and hiring of senior employees in marketing and IT functions are steps in the right direction.
Regards
Team Marcellus

Disclaimer:

Copyright © 2026 Marcellus Investment Managers Pvt Ltd, All rights reserved

Note: the above material is neither investment research, nor investment advice. Marcellus does not seek payment for or business from this material/email in any shape or form. Marcellus Investment Managers Private Limited (“Marcellus”) is regulated by the Securities and Exchange Board of India (“SEBI”) as a provider of Portfolio Management Services. Marcellus is also a US Securities & Exchange Commission (“US SEC”) registered Investment Advisor. No content of this publication including the performance related information is verified by SEBI or US SEC. If any recipient or reader of this material is based outside India and USA, please note that Marcellus may not be regulated in such jurisdiction and this material is not a solicitation to use Marcellus’s services. This communication is confidential and privileged and is directed to and for the use of the addressee only. The recipient, if not the addressee, should not use this material if erroneously received, and access and use of this material in any manner by anyone other than the addressee is unauthorized. If you are not the intended recipient, please notify the sender by return email and immediately destroy all copies of this message and any attachments and delete it from your computer system, permanently. No liability whatsoever is assumed by Marcellus as a result of the recipient or any other person relying upon the opinion unless otherwise agreed in writing. The recipient acknowledges that Marcellus may be unable to exercise control or ensure or guarantee the integrity of the text of the material/email message and the text is not warranted as to its completeness and accuracy. The material, names and branding of the investment style do not provide any impression or a claim that these products/strategies achieve the respective objectives. Further, past performance is not indicative of future results. Marcellus and/or its associates, the authors of this material (including their relatives) may have financial interest by way of investments in the companies covered in this material. Marcellus does not receive compensation from the companies for their coverage in this material. Marcellus does not provide any market making service to any company covered in this material. In the past 12 months, Marcellus and its associates have never i) managed or co-managed any public offering of securities; ii) have not offered investment banking or merchant banking or brokerage services; or iii) have received any compensation or other benefits from the company or third party in connection with this coverage. Authors of this material have never served the companies in a capacity of a director, officer or an employee.

This material may contain confidential or proprietary information and user shall take prior written consent from Marcellus before any reproduction in any form.

Regards, Team Marcellus

If you want to read our other published material, please visit https://marcellus.in/pms-investment-blog/


Copyright © 2026 Marcellus Investment Managers Pvt Ltd, All rights reserved


RELATED NEWSLETTERS

  • Aug 12, 2026

    Marcellus Portfolio Updates & Insights – August 2026

    READ MORE
  • Aug 06, 2026

    Global Compounders: Why have we underperformed the S&P500 in 2026?

    READ MORE
  • Jul 27, 2026

    Isaac Newton and the Madness of Men

    READ MORE

RELATED NEWSLETTERS

  • Aug 12, 2026

    Marcellus Portfolio Updates & Insights – August 2026

    READ MORE READ MORE
  • Aug 06, 2026

    Global Compounders: Why have we underperformed the S&P500 in 2026?

    READ MORE READ MORE
  • Jul 27, 2026

    Isaac Newton and the Madness of Men

    READ MORE READ MORE
PREV ISSUE

The Science Behind Portfolio Concentration


Published on Apr 05, 2021
NEXT ISSUE

Simplifying Life Insurance and why we hold HDFC Life


Published on Apr 18, 2021

Did`t receive OTP? 00:00 Resend
Did`t receive OTP? 00:00 Resend
Be the First to Know

Marcellus logo

At Marcellus, our Purpose is to make wealth creation simple and accessible by being trustworthy and transparent capital allocators.

  • Twitter-Marcellus Investment
  • LinkedIn-Marcellus Investment

Marcellus Investment Managers Private Limited

Please reach out to us at

Board Line : 0806-9199-400

Sales Desk: 0806-9199-401

e-mail: invest@marcellus.in


Marcellus Investment Managers
102, First Floor, Boston House, Suren Road,
Near 'Western Express Highway' Metro Station,
Andheri East, Mumbai 400093

Please reach out to us at

e-mail: help.gift@marcellus.in


Marcellus Investment Managers
IFSC Branch – Unit no. 431 and 432, Signature Building, Fourth Floor, Block 13B, Zone-1, GIFT SEZ, GIFT City, Gandhinagar – 382 355/382 050

  • Home
  • Our Team
  • Invest with us
  • GIFT City Corporate Disclosures
  • Marketing Disclosure
  • Investing Books
  • FAQs
  • Videos
  • Newsletters
  • Corporate Regulatory Disclosure
  • Company Information
  • Terms & Conditions
  • Privacy Policy
  • Responsible Investing
  • Contact Us

2026 © | All rights reserved.

Privacy Policy | Terms and Conditions

Please read the following carefully and select your residency jurisdiction


If accessing this website by giving false declaration, the person shall be solely liable/responsible for any adverse consequences suffered, legally as well as financially, pursuant to use of any information contained in this website

Beware of fraudulent websites and applications!

Marcellus or its employees will never ask you to join WhatsApp groups or social media accounts created by or on behalf of Marcellus. Marcellus does not have any App facilitating trading in securities, nor does Marcellus issue any advertisement for investment in any specific stocks or for any cash transactions.

If you come across any such activity, please report to the appropriate law enforcement authorities, and inform us on compliance@marcellus.in.

Click here for the list of our official social media handles.

Close